scholarly journals Breast Cancer from Molecular Point of View: Pathogenesis and Biomarkers

10.5772/24940 ◽  
2011 ◽  
Author(s):  
Seyed Nasser ◽  
Maliheh Pars
Keyword(s):  
Breast Cancer ◽  
Point Of View

scholarly journals Iterative Variable Selection for High-Dimensional Data: Prediction of Pathological Response in Triple-Negative Breast Cancer

Mathematics ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 222
Author(s):  
Juan C. Laria ◽  
M. Carmen Aguilera-Morillo ◽  
Enrique Álvarez ◽  
Rosa E. Lillo ◽  
Sara López-Taruella ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Variable Selection ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
A Priori ◽  
Simulated Data ◽  
Point Of View ◽  
High Dimensional ◽  
Whole Genome ◽  
Genome Context

Over the last decade, regularized regression methods have offered alternatives for performing multi-marker analysis and feature selection in a whole genome context. The process of defining a list of genes that will characterize an expression profile remains unclear. It currently relies upon advanced statistics and can use an agnostic point of view or include some a priori knowledge, but overfitting remains a problem. This paper introduces a methodology to deal with the variable selection and model estimation problems in the high-dimensional set-up, which can be particularly useful in the whole genome context. Results are validated using simulated data and a real dataset from a triple-negative breast cancer study.

Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1

2009 ◽  
Vol 62 (7) ◽  
pp. 624-628 ◽  
Author(s):  
S Pintens ◽  
P Neven ◽  
M Drijkoningen ◽  
V Van Belle ◽  
P Moerman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Point Of View

Breast cancer screening: another point of view

2005 ◽  
Vol 14 (1) ◽  
pp. 1-5 ◽  
Author(s):  
J R de la Haba Rodríguez ◽  
R M Chamorro ◽  
M J M Vidal ◽  
R S Blanch ◽  
L T Beltrán ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Point Of View

scholarly journals Taxane therapy in the adjuvant treatment of breast cancer in Italy: economic evaluation

2006 ◽  
Vol 7 (1) ◽  
pp. 63-69
Author(s):  
Simona Ravera ◽  
Lorenzo G. Mantovani
Keyword(s):  
Breast Cancer ◽  
Cost Minimization ◽  
Disease Free Survival ◽  
Developed Countries ◽  
Preventive Therapy ◽  
Point Of View ◽  
Adjuvant Setting ◽  
Screening Programs ◽  
Equivalent Efficacy ◽  
Dosing Regimens

Breast cancer (BC) is one of the leading cause of death in developed Countries and every year more than a million new cases are diagnosed worldwide. In Italy the prevalence of BC was estimated to be 1,070 per 100,000 at 31 December 1992. Nevertheless, despite the increase in incidence, mortality rate for BC are decreased in the last decades probably due to several factors such as implementation of screening programs, early diagnosis and new adjuvant therapies. Important types of adjuvant chemotherapy include anthracyclines and taxanes and these treatments continue to be evaluated to determine optimal combinations and dosing regimens. The efficacy of paclitaxel and docetaxel in adjuvant setting for the treatment of early BC has been assessed in different trials where the two taxanes showed a significant increase in both Disease Free Survival (DFS) and Overall Survival (OS) in comparison with nontaxane therapy. In particular results from one of the last studies comparing paclitaxel and docetaxel show equivalent efficacy for both drugs. At the light of the recent findings, the objective of this work is to perform a cost minimization analysis of paclitaxel vs docetaxel in the adjuvant setting for treatment of early BC in Italy. The analysis was conducted from the National Health Service’s point of view, assuming equivalent efficacy in terms of DFS and OS for both taxanes. Costs were evaluated on the basis of therapeutic schemes used in the analyzed trials. Results show that paclitaxel, administered every 3 weeks for 4 cycles after doxorubicin and cyclophosphamide, represents the less costly therapy. This is a conservative costs estimate based on data from literature that does not take into account possible additional costs associated to the treatment of febrile neutropenia (FN) as adverse event related to chemotherapy. Since, on the basis of scientific literature data, FN seems to be more related with docetaxel than with paclitaxel administration, it is likely that in clinical practice the Growth–Colony Stimulating Factor is often prescribed as a preventive therapy when Docetaxel is administred, giving rise to treatment costs.

scholarly journals Perceived Proximity and Distance in the Doctors-Patients Relationships : Application to the Breast Cancer Treatment Case

K@iros ◽  
2019 ◽  
Author(s):  
Patrick RALET ◽  
◽  
Pascal BRASSIER ◽  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Breast Cancer Treatment ◽  
Point Of View ◽  
Patient Relationship ◽  
Doctor Patient Relationship ◽  
Treatment Pathway ◽  
The Relationship

An obvious questioning of the doctor-patient relationship leads us to conduct a research on the point of view of patients who have had to follow a breast cancer treatment pathway. We want to know to what extent the notions of distance/proximity make it possible to explain the doctors-patients relationships, and on what realities it is based. It appears that the answer is complex, multifaceted, and rather poses the question of the dimensions of the relationship alongside the medical protocol.

scholarly journals THE MODERN ASPECTS OF THE BREAST CONSERVING SURGERY AFTER NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER CT1-3N0-3M0

2020 ◽  
Vol 66 (4) ◽  
pp. 376-380
Author(s):  
Nadezhda Volchenko ◽  
A. Bosieva ◽  
A. Zikiryakhodzhayev ◽  
M. Ermoshchenkova
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Neoadjuvant Chemotherapy ◽  
Breast Conserving Surgery ◽  
Point Of View ◽  
Medical Documentation ◽  
Oncological Safety ◽  
Lobular Cancer ◽  
Significant Difference ◽  
Disease Free

Introduction. While the “no tumor on ink” approach is generally accepted for breast-conserving surgery (BCS) in patient with breast cancer, it remains unclear whether it is oncologically safe for BCS after neoadjuvant chemotherapy therapy (NACT). The aim of the study is to investigate the optimal width of the resection edges in BCS after NALT and the influence on disease-free and overall survival in patients with breast cancer. Materials and methods. Retrospectively, the medical documentation of 76 patients with breast cancer, who were performed BCS after NACT, was studied. The distribution by stage of breast cancer was as follows: I St. -5 patients, II St. - 55, III St. - 16 (excluded IIIB St.). Invasive cancer of non-specific type was diagnosed in 81.6% of cases, in 6.5% - lobular cancer, in 1.3% - combined breast cancer. Radical breast resections in the classic version were performed in 28 cases, and oncoplastic resections in various modifications were performed in 48 Cases. Results. We present the retrospective data of 76 patients with breast cancer who underwent OSA after NALT in the Department of breast and skin cancer OF the Moscow Institute of medical research. P. A. Herzen. The results of our study demonstrated the oncological safety of OSO with respect to new sizes of tumor nodes after NALT followed by remote radiotherapy. The method of “absence of tumor cells” at the edges of resection demonstrated a high percentage of 1, 3, 5-year relapse - free and overall survival, the frequency of relapse was 2.6%. There was no statistically significant difference in 1, 3, 5-year relapse-free and overall survival when the width of the resection edges was more or less than 1 mm. Conclusion. The results of numerous studies have demonstrated that the breast- conserving surgery is the safe method of surgical treatment from an oncological point of view and is an alternative for radical mastectomies for patients with the breast cancer after neoadjuvant chemotherapy.

Cathepsin D in Breast Cancer Tissue

1990 ◽  
Vol 5 (4) ◽  
pp. 203-206 ◽  
Author(s):  
P. Gonzalez Gancedo ◽  
M.L. G-Casaus ◽  
J. Ruiz Cacho ◽  
F. Calero ◽  
J.M. Inocente ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cathepsin D ◽  
Clinical Stage ◽  
Point Of View ◽  
Axillary Lymph Nodes ◽  
Cancer Tissue ◽  
Axillary Lymph ◽  
Statistical Point ◽  
High Concentrations ◽  
Dependent State

The cathepsin D concentration in 18 women with benign breast pathology has a cut-off value of 43 pmol/mg of protein. High values have been detected in two cases of chronic mastitis. These high values of cathepsin D were found in a study of 62 patients suffering from breast cancer and are independent of the hormone dependent state of the tumour. The cathepsin D concentration may have a prognostic function in breast cancer determination, as high concentrations are found in combination with other prognostic factors such as clinical stage, size of the tumour, state of the axillary lymph nodes and in the histological differentiation grade, where from a statistical point of view, the combination is important.

Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view

2006 ◽  
Vol 16 (s2) ◽  
pp. 505-510 ◽  
Author(s):  
P. NEVEN ◽  
R. PARIDAENS ◽  
F. AMANT ◽  
H. WILDIERS ◽  
P. BERTELOOT ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Point Of View ◽  
Er Positive ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document